Phase i trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer
Antineoplastic Combined Chemotherapy Protocols
The MTD of erlotinib with FOLFOX4 with or without bevacizumab is 100 mg daily. The regimen appeared to increase toxicity but showed activity in patients with CRC.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency